Treatment decisions in essential tremor turn on one question: how much is the tremor interfering with your life? Mild tremor that is mostly a nuisance may need nothing more than trigger management or a single medication used only for high-stakes moments. Tremor that is disrupting eating, writing, work, or independence justifies climbing higher — through optimized and combined medications, and eventually to a procedure for tremor that stays disabling despite a genuine drug trial (Shanker, BMJ, 2019).
Two principles run through the whole ladder. First, the goal is function, not a perfectly still hand — steadier eating and more legible writing are realistic wins; complete abolition of tremor usually is not. Second, response is individual: the same drug that transforms one person's tremor does little for the next, which is exactly why the ladder exists. The tension patients live is captured well in the community:
That feeling — a drug that half-works and a big next step that feels premature — is precisely the middle of the ladder this guide is meant to make navigable.
Two drugs sit at the base of the ladder, and they are the only two the American Academy of Neurology grades Level A for essential tremor (Zesiewicz et al., Neurology, 2011). Propranolol is a beta-blocker; in controlled trials it was significantly more effective than placebo (Baruzzi et al., Neurology, 1983). Primidone is an anti-seizure medication whose effectiveness in hand and head tremor was confirmed in a double-blind trial (Findley et al., J Neurol Neurosurg Psychiatry, 1985). Either can be started first, and the choice is usually driven by other health factors more than by a clear efficacy winner.
The honest expectation for either drug is a partial win. Short-term studies place tremor reduction in a moderate range rather than near-elimination, and pushing the dose higher does not reliably buy more benefit — so the realistic target is a steadier hand for daily tasks, set that way from the start. Primidone in particular is started at a very low bedtime dose and increased slowly, because its first-dose reaction is the single most common reason people abandon an otherwise useful drug.
This is the most important rung on the ladder, because it is where the largest share of people actually are. First-line therapy is inadequate for an estimated 25% to 55% of patients (Bruno et al., Cochrane, 2017) — either it never controlled the tremor well, or a drug that once worked seems to be fading. That fading is worth understanding: it is more often the tremor slowly progressing past a fixed dose than the body becoming tolerant to the drug, and dose adjustment or adding a second agent frequently restores control.
One safety point belongs here in bold: never stop propranolol or primidone abruptly. Beta-blockers in particular can cause rebound effects if stopped suddenly, so any change should be doctor-guided and tapered. When a first-line drug is genuinely not enough, the structured next steps are to optimize its dose, switch to or add the other first-line agent, then move to second-line options — and to keep the procedure conversation on the table if the tremor remains disabling.
When the first-line pair is exhausted or not tolerated, several second-line drugs are used, though their evidence is thinner and more mixed than propranolol's and primidone's (Hopfner & Deuschl, Neurotherapeutics, 2020). Topiramate has the most studied second-line evidence, including placebo-controlled trials (Bruno et al., Cochrane, 2017), though it carries its own tolerability trade-offs. Gabapentin and certain benzodiazepines are also used, typically as add-ons or when other options don't fit.
The practical logic of this rung is combination and individualization rather than a clear ranking: a second drug may be added to a partially effective first one, and the choice is shaped as much by a person's other conditions and side-effect tolerance as by any head-to-head superiority. If several medications in sequence — used at adequate doses — still leave the tremor disabling, that is the medical signal that the ladder's next section, procedures, deserves a serious look.
One targeted option sits slightly apart from the oral drugs: botulinum toxin injections. They are not a general treatment for hand tremor, but for specific tremor distributions — particularly head tremor and voice tremor that oral medication handles poorly — injections into the relevant muscles can reduce the tremor, and the AAN evidence review recognizes botulinum toxin as an option for these distributions (Zesiewicz et al., Neurology, 2011). The trade-off for limb use is dose-dependent weakness in the injected muscles, which is why it is reserved for cases where the tremor's location makes it a good fit rather than used as a first choice.
For tremor that stays disabling despite a real medication trial, two procedures can substantially reduce it, and both work on the same target — the VIM (ventral intermediate) nucleus of the thalamus. Deep brain stimulation (DBS) implants a thin electrode there, connected to a pacemaker-like device that delivers adjustable stimulation. MRI-guided focused ultrasound (FUS) uses focused sound waves to create a tiny lesion in the same spot with no incision; a randomized trial confirmed it significantly reduces tremor compared with a sham procedure (Elias et al., NEJM, 2016).
DBS benefit is genuinely durable in aggregate but not static: an observer-blinded long-term study found the stimulation effect declined with time since surgery, a pattern partly reflecting habituation and partly the disease progressing (Paschen et al., Neurology, 2019). That waning — reported in anywhere from 0% to 73% of patients depending on how it's defined — is usually managed with reprogramming rather than being a reason to avoid the procedure (Fasano & Helmich, Mov Disord, 2019). FUS trades DBS's adjustability for a one-time, incisionless treatment with immediate results. Neither is a cure, and the choice between them is a genuine decision to make with a specialist.
Both procedures carry real, if generally manageable, risks that belong in the decision. Because they act on the same thalamic region that sits near pathways for speech and balance, the most relevant side effects for either are slurred speech, numbness or tingling, and unsteadiness or gait disturbance; with DBS these are often adjustable by reprogramming, while with focused ultrasound they stem from a fixed lesion. DBS adds the risks that come with implanted hardware — a small chance of infection, lead problems, or the need for battery changes over the years. These are the trade-offs a candidate weighs against how disabling the tremor has become, which is exactly why the decision is made with a movement-disorders team rather than in the abstract.
A procedure becomes reasonable to consider when two thresholds are met together: the tremor is genuinely disabling — interfering with eating, writing, work, or independence — and medication has been given a fair trial and fallen short. Neither threshold alone is enough; a mild tremor rarely warrants surgery, and a disabling tremor that hasn't had an adequate drug trial usually deserves one first (Shanker, BMJ, 2019).
What counts as "an adequate trial" is worth pinning down: it generally means both first-line drugs tried at meaningful doses (alone and often together), and typically a second-line agent, before the tremor is called medication-refractory. From there, candidacy is assessed by a specialist team, and the DBS-versus-FUS choice is weighed on the trade-offs above — adjustability and bilateral treatment versus an incisionless one-time procedure. This is a decision to reach with a movement-disorders neurologist, not alone.
Deciding on a procedure isn't the end of the road — there is usually a wait before it and an adjustment period after, and both are manageable windows rather than dead time. While waiting, the priorities are to stay on your current medication (not stop it in anticipation), keep triggers like fatigue and excess caffeine in check, and lean on adaptive strategies for daily tasks. It is also the moment to prepare practical questions for the surgical team.
After a procedure, the key expectation to set is that benefit often builds rather than switching on instantly. DBS in particular is typically activated weeks after surgery and then tuned over several visits, so the full effect arrives gradually. Knowing that in advance prevents the early weeks from feeling like a disappointment when they are simply the normal ramp.
Alongside every rung of the ladder sit supportive measures that lower day-to-day impact without treating the tremor's source. Managing known triggers helps: fatigue, stress, and caffeine reliably worsen action tremor, so rest, stress reduction, and moderating caffeine buy real steadiness for some people. An occupational therapist is the specialist for adaptive technique — matching tools and strategies to your particular tremor for eating, writing, and other tasks — and is one of the higher-value, lowest-risk referrals available.
Wearable tremor-stabilizing devices are a developing category worth asking a neurologist about, as a complement to — not a replacement for — the treatments above. Across all of it, the honest framing is the one this guide opened with: essential tremor is managed, not cured, and success means meaningfully steadier daily life. Set against that yardstick, most people can find a combination on this ladder that gives them back a good deal of what the tremor took.